

To the Editor-in-chief and the Science Editor of the *World Journal of Gastroenterology*,

Re: Submitted manuscript entitled "**Updates on the management and treatment of viral hepatitis**".

[Manuscript NO: 62614]

We would like to thank the editor and reviewers for the helpful comments on our submitted manuscript. In accordance with them, we have revised the manuscript and provide a point-by-point response to the comments below. All the changes in the original manuscript are highlighted in the revised version submitted. We hope the manuscript now meets the standard expected of the *World Journal of Gastroenterology*.

Sincerely,

Yuri Boteon (on behalf of all co-authors)

In response to Science Editor

We thank the editor for the comments. In accordance, we have provided a nonstructured abstract and attached in the submission the original figure in PowerPoint format. We confirm this is an original figure, thus permission for the use is not required. Reference's numbers were put in brackets and made superscript. All related documents as audio core tip, biostatistics review certificate, conflict of interest disclosure form, and copyright license agreement.

In response to Reviewer 1

Comments to the authors: This manuscript contains no new evidence-based data. However, it contains very useful information for readers interested in Hepatology. Therefore, I think it would be appropriate to publish it.

Response: We appreciated the complimentary comments from the reviewer. Thanks for spending your valuable spare time reviewing the manuscript.

Reviewer 2

Comments to the authors: The authors didn't comment on Lamivudine therapy for HBV.

Response: We thank the reviewer for the thoughtful analysis of the work. In accordance, the current role of Lamivudine on the treatment of chronic hepatitis B was discussed in the manuscript.

Comments to the authors: The author didn't mention the other medications which have been recently approved to treat certain genotypes of hep C. For example, • Harvoni (ledipasvir/sofosbuvir) is approved for genotypes 1, 4, 5, and 6. • Technivie (ombitasvir/paritaprevir/ritonavir) is approved for genotype 4. • Zepatier (elbasvir/grazoprevir) is approved for genotypes 1 and 4.

Response: We highly appreciate the reviewer's comment. In accordance, the medications approved for specific genotypes of hepatitis C virus were mentioned appropriately in the main text (Harvoni™ and Zepatier™). The medication Technivie™ was discontinued by AbbVie on May 22, 2018.

Comments to the authors: Also, the author didn't mention the New Hepatitis Delta Treatment (Hepbtaik) which has been approved by European Commission on September 2, 2020 in Europe

Response: We thank the reviewer for the recommendation. A comprehensive discussion on hepatitis delta treatment was included in the manuscript.

Reviewer 3

Comments to the authors: Comments for ESPS Manuscript NO 62614 This review paper is interesting. I have no other comment. But, the language of this paper needs further polishing.

Response: We appreciated the complimentary comments from the reviewer. Thanks for spending your valuable spare time reviewing the manuscript. The paper has been carefully revised and the language was polished.

Reviewer 4

Comments to the authors: Please make the following corrections Page 3 – replace past with last Page 4 – replace chronification with – to become chronic Page 5 – 71 million of HCV (not HDV) Page 13 - more information about HDV treatment and new development in this field – the frequency of this disease is increasing in the world (due to immigration) Page 13up – immigration for HDV endemic region (not HCV) Page 16 – conclusions – replace advent with results

Response: We highly appreciated the reviewer's comments. All the corrections and substitutions required were performed.